Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER vs Risperidone IR on Cognitive Domains in Schizophrenia
NCT01670071Phase 4Terminated
- Sponsor
- Johnson & Johnson
- Start
- Jan 2013
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of paliperidone in schizophrenia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Change in category fluency score of Cognitive Abilities Screening Instrument, Chinese version (CASI C-2.0) at 24 weeks. Started Jan 2013; status: terminated.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01670071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01670071.